Orchid Pharma Limited has informed the Exchange about Credit Rating
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings has reviewed Orchid Pharma's credit ratings on August 6, 2025, and maintained them without any downward revision. The rating for Long Term Bank Facilities of ₹207.50 crore stays at CARE A- (RWD), the Long Term/Short Term Bank Facilities of ₹75.00 crore stays at CARE A-/CARE A2 (RWD), and Short Term Bank Facilities of ₹84.00 crore stays at CARE A2 (RWD). All ratings continue on 'Rating Watch with Developing Implications.' Total rated facilities amount to ₹366.50 crore. The review considered FY25 operational and financial performance, the proposed merger with Dhanuka Laboratories, and the proposed acquisition of Allecra Therapeutics assets. CARE has stated it will take a final view once the implications of these developments on the company's credit profile become clear.
This is a neutral to mildly positive update for shareholders — the company has avoided a credit downgrade, preserving its investment-grade ratings. However, the 'Rating Watch with Developing Implications' status creates some uncertainty, as future revisions will depend on the outcomes of the proposed Dhanuka merger and the Allecra Therapeutics asset acquisition.